However, a translational clinical trial demonstrated high-level FGFR2 amplification to predict response to the FGFR inhibitor AZD4547 in gastric cancer28; thus the association of CNAs with response to FGFR inhibitors may be gene- and tumor type-specific. This evidence concerns the gene FGFR2 and neoplasm.